Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial. The trial is evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy/DMD amenable to exon 51 skipping. The DELIVER trial also provided new positive long-term clinical data from its ongoing open-label extensio ...